PERSPECTA

News from every angle

← Back to headlines

Arbutus Biopharma's Moderna Settlement and Biotech Advantage

The article explores whether Arbutus Biopharma Corporation can leverage its settlement with Moderna, Inc. into a long-term competitive advantage within the biotechnology sector.

11 Aug, 00:18 — 11 Aug, 00:18
PostShare

Sources

Showing 1 of 1 sources
YahooMostly Factual7d ago

Could Arbutus Biopharma Corporation (ABUS) Turn its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech Advantage?

Read full article →

Related Stories

Family Business in Co Wexford Decimated by Fire

25m ago

Iceland's Central Bank Expected to Announce Interest Rate Hike

30m ago

Goldman Sachs Expands Asset Management with LCN Capital Partners Acquisition

34m ago

US Coast Guard Lifts 12-Year Entry Restriction on Nigeria-Bound Ships

53m ago